Evaluation of exposure to antimicrobials in both subsets of patients according to the therapeutic strategy employed
| Exposure to antimicrobials | Patients empirically treated (n=152) | Patients treated according to antigen results (n=25) |
| Broad-spectrum antimicrobials | ||
| Ceftriaxone, IV | 35.9 | 35.2 |
| Levofloxacin, IV | 16.1 | 15.8 |
| Levofloxacin, oral | 26.1 | 0 |
| Amoxicillin–clavulanate, IV | 3.3 | 4.4 |
| Amoxicillin–clavulanate, oral | 69.6 | 10.0 |
| Cefditoren, oral | 36.7 | 4.0 |
| Total | 187.7 | 69.4 |
| Narrow-spectrum antimicrobials | ||
| Azithromycin, IV | 32.8 | 35.0 |
| Azithromycin, oral | 15.8 | 11.1 |
| Amoxicillin, oral | 0 | 176.4 |
| Total | 48.6 | 222.5 |
Data are presented as defined daily doses per 100 patient days.
IV, intravenous.